Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis.

Authors :: Caocci G
Mulas O
Annunziata M
Luciano L
Bonifacio M
Orlandi EM
Pregno P
Galimberti S
Russo Rossi A
Abruzzese E
Iurlo A
Martino B
Sgherza N
Binotto G
Castagnetti F
Gozzini A
Fozza C
Bocchia M
Sicuranza A
Stagno F
Efficace F
Usala E
De Gregorio F
Scaffidi L
Elena C
Pirillo F
Baratè C
Trawinska MM
Cattaneo D
Labate C
Gugliotta G
Molica M
Specchia G
La Nasa G
Foà R
Breccia M
Source :: American journal of hematology [Am J Hematol] 2018 Jul; Vol. 93 (7), pp. E159-E161. Date of Electronic Publication: 2018 Apr 28.
Publication Year :: 2018

Subjects :: Adolescent
Adult
Aged
Aged, 80 and over
Cardiotoxicity etiology
Female
Humans
Italy
Male
Middle Aged
Protein Kinase Inhibitors therapeutic use
Protein-Tyrosine Kinases antagonists & inhibitors
Risk Assessment
Risk Factors
Young Adult
Cardiotoxicity prevention & control
Leukemia, Myelogenous, Chronic, BCR-ABL Positive complications
Protein Kinase Inhibitors toxicity

Full Text Access

Tools